Evaluating medication adherence and testosterone suppression in patients with prostate cancer treated with relugolix: Results from the OPTYX study.

Authors: Daniel Eidelberg Spratt, Rana R. McKay, Benjamin H. Lowentritt, Ashley Ross, Juscilene Menezes, Yi Zhong, Abhishek Kavati, Michael Ryan, Michele Cole, Tanya B. Dorff

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17106

Source: Full article

---

Abstract

e17106